TCGC: Clinical Genome Conference TCGC: Clinical Genome ConferenceTCGC: Clinical Genome Conference

본 컨퍼런스는 참가 신청이 마감되었습니다.

TCGC: The 4th Annual Clinical Genome Conference 2015
- TCGC:제4회 임상 게놈 컨퍼런스 2015 -
2015년 6월 22 - 24일
미국 캘리포니아주 샌프란시스코, Hotel Kabuki

차세대 시퀀싱 플랫폼의 신뢰성, 견고성, 재생성은 이제 의심의 여지가 없으며, 게노믹스의 임상 도입은 현실화되고 있습니다. 그러나 게놈 정보를 의료의 진전으로 성공적으로 이동하여 임상에 활용하기 위해서는 많은 문제가 남아 있습니다.

Bio-IT World와 Cambridge Healthtech Institute는 제4회 컨퍼런스 TCGC: The Clinical Genome Conference를 다시 개최합니다. 본 컨퍼런스에서는 임상 게노믹스에 영향을 미치는 이해관계자들이 참가하여 임상 게놈 의료의 응용을 확대하기 위한 새로운 연구 결과 및 솔루션을 공유합니다.


아젠다

첫째날 | 둘째날 | 셋째날

6월 22일(월)


9:00 am 쇼트코스 등록 개시 및 모닝커피

10:00 am-1:00 pm 쇼트코스


2:00 컨퍼런스 등록 개시

3:00 의장 개회사

Eric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center


기조 세션

3:15 키홀에서 게놈 원더랜드로의 이동:상식, 심상치 않은 넌센스를 초월

Nathaniel PearsonNathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome Center

One hundred fifty years after Gregor Mendel first systematically probed genetic heritability, we risk forgetting a key insight from his work, in our rush to broaden clinical genomics from urgent diagnosis for a few to lifelong care for all. By fully embracing that insight now, we can wisely bolster our health infrastructure for the long haul.

4:00 웰니스의 진화를 위한 예방의학과 맞춤형 의료의 원칙 통합

Nathan PriceNathan D. Price, Ph.D., Associate Director, Institute for Systems Biology

Future medicine will be more proactive and data-rich than anything before possible - and will focus on maintaining and enhancing wellness more than just reacting to disease. We have launched a large-scale 100K wellness project that integrates genomics, proteomics, transcriptomics, microbiomes, clinical chemistries and wearable devices to monitor wellness and disease. I will present results from our pilot study of 107 individuals, showing how this data led to actionable findings for individuals to improve health and reduce risk drivers of disease.

4:45 중개 암 게놈의 빅데이터

Laura J. van 't VeerLaura J. van 't Veer, Ph.D., Director, Applied Genomics and Angela and Shu Kai Chan Endowed Chair, Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Molecular genomics contributes to the knowledge of who is at risk to develop cancer, how external factors may influence this risk, whether tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy. Dr. van 't Veer's current research involves integrating various types of genomics data, including next-generation sequencing big data, and is aimed at understanding the molecular basis for early response to therapy as a surrogate for long-term survival prediction.


5:30 전시회장 환영 리셉션과 포스터 관람

6:30 첫째날 종료


첫째날 | 둘째날 | 셋째날

6월 23일(화)

7:00 am 조찬 프레젠테이션 또는 모닝커피


게노믹스가 유도하는 암치료

8:00 의장 인사

Nathaniel Pearson, Ph.D., Senior Director, Scientific Engagement & Public Outreach, New York Genome Center


8:05 특별 프레젠테이션:CIViC:암 이형의 임상적 해석

MalachiGriffithMalachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of Medicine

To realize the potential of personalized medicine, genomic aberrations must be placed in the context of therapeutic response and diagnostic or prognostic associations. The evidence for these associations must be captured and characterized so that we can achieve a principled consensus among genomic experts, pathologists and oncologists on how best to interpret a genomic alteration in a clinical context. To this end, we present CIViC as a forum for the clinical interpretation of variants in cancer.


8:35 비소세포 폐암에서 DNA 재배열을 이용한 독립적 원발종양과 폐내 전이 식별

GeorgeVasmatzisGeorge Vasmatzis, Ph.D., Assistant Professor, Laboratory Medicine & Pathology, Mayo Clinic & Foundation

Distinguishing independent primary tumors from intrapulmonary metastases in non-small cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement-based approach to differentiate multiple primary tumors from metastasis. A total of 41 tumor samples were sequenced. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. Concordance between histology and genomic data occurred in the majority of cases. Discrepant cases were resolved by genome sequencing.

9:05 개인맞춤형 유방암 예방에서 게놈 시퀀싱의 역할

WeivaSiehWeiva Sieh, M.D., Ph.D., Assistant Professor, Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine

The benefits of genome sequencing for guiding personalized preventive strategies at the population level are uncertain. We evaluated the benefits and harms of targeting preventive efforts to the subpopulation of women whose genomes put them at highest risk of breast cancer using mathematical models for (1) 86 currently known breast cancer susceptibility alleles and (2) assuming complete knowledge of all breast cancer genes. Our findings suggest that genome sequencing has the potential to guide personalized breast cancer prevention, and that the benefits will improve with increased understanding of the genetic etiology of breast cancer.

9:35 타이틀은 추후 발표

David Jackson, Ph.D., Chief Innovation Officer, Molecular Health

9:50 스폰서 프레젠테이션

10:05 전시회장 휴식시간과 포스터 관람

10:45 전립선암의 유전적 리스크를 이해하기 위한 유전자 데이터 및 에피제네틱 데이터의 통합

BogdanPasaniucBogdan Pasaniuc, Ph.D., Assistant Professor, Pathology & Laboratory Medicine and Human Genetics, David Geffen School of Medicine, University of California, Los Angeles

Although genome-wide association studies have identified over 100 genetic loci that increase risk for developing prostate cancer, their functional effects on risk remain largely unknown. I present new approaches that integrate large-scale genetic data with cell-type-specific epigenetic functional annotation data to gain insights into the genetic architecture of prostate cancer risk.

11:15 딥 시퀀싱에 의한 순환 종양 DNA의 초고감도 탐지

MaxDiehnMaximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford University

Circulating tumor DNA (ctDNA) represents a promising biomarker for detection and monitoring of cancers. Work on clinical applications of next-generation sequencing-based ctDNA quantitation will be discussed.


Genospace11:45 타이틀은 추후 발표。

12:15 pm 휴식시간

12:30 오찬 프레젠테이션 또는 개별 점심식사


"웰니스"의 이해

2:00 의장 인사

Malachi Griffith, Ph.D., Associate Director, The Genome Institute; Assistant Professor, Genetics, Washington University School of Medicine

2:05 평생 건강 자원으로서의 전 게놈 시퀀스 어프로치

SekWonKongSek Won Kong, M.D., Assistant Professor, Medicine/Informatics Program, Harvard Medical School and Boston Children's Hospital

Accumulated genomic variants provide a foundation of information in the context of precision medicine, and an individual genome can be a resource for lifelong well being. To achieve analytical validity of whole-genome sequence for clinical use, a reproducible and accurate analysis and interpretation pipeline is required. Carrier status of disease-causing mutations and pharmacogenomic variants are of primary interest; however, estimating genetic liability for complex diseases using established risk alleles might be informative. We demonstrate how complex trait risk variants from an individual genome can be summarized and reported for the general clinician and patients.

2:35 세계 최고령자등의 전 게놈 시퀀싱

KristenFortneyKristen Fortney, Ph.D., Research Scientist, Stuart K. Kim Laboratory, Developmental Biology, Stanford University

Supercentenarians (110 years or older) are the world's oldest people. We sequenced the genomes of 17 supercentenarians to see if we could uncover the genetic basis for their extreme longevity. From this small sample size, we were unable to find rare protein-altering variants significantly associated with extreme longevity. We have made the complete genomes of all 17 supercentenarians available as a resource to assist discovery in future studies.

3:05 스폰서 프레젠테이션

3:35 전시회장 휴식시간과 포스터 관람

4:15 임상 샘플의 딥 메타게노믹스 시퀀싱 이해

ArunRawatArun Rawat, Ph.D., Bioinformatician II, Translational Genomics Research Institute

Decreasing cost of next-generation sequencing provides unique opportunities to identify host-associated microbial communities in clinical samples. Our goal is to understand the unknown etiologic agent in symptomatic patients to allow faster clinical decisions. Prediction of undiagnosed disease is possible with high reliability despite the variability in metagenomic samples and computational challenges.

4:45 개인 건강을 증진하기 위한 생식세포 게노믹스의 활용

JohnWitteJohn S. Witte, Ph.D., Professor, Epidemiology & Biostatistics and Urology; Head, Division of Genetic and Cancer Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader, Cancer Center Program in Cancer Genetics, University of California, San Francisco



5:15 양방향 그룹 토론회

Wrap up the day with a moderated discussion group to brainstorm the translation of genomic technologies into the clinic. Use this opportunity to share new findings, propose solutions and develop collaborations with the diverse stakeholders advancing genomic medicine.

6:00 둘째날 종료


첫째날 | 둘째날 | 셋째날

6월 24일(수)

7:00 am 조찬 프레젠테이션 또는 모닝커피


임상 시퀀싱:적절한 투자?

8:00 의장 인사

Katherine Tynan, Ph.D., Business Development & Strategic Consulting for Diagnostics Companies, Tynan Consulting LLC

8:05 차세대 게놈 시퀀싱으로부터 부수적 연구 결과 회수시 비용 효율 평가

CarolineBennetteCaroline Bennette, MPH, Ph.D., K12 Patient-Centered Outcomes Research Scholar, Group Health Research Institute, University of Washington

Our team at the University of Washington recently developed a decision-analytic policy model to evaluate the potential clinical and economic impact of returning ACMG-recommended incidental findings from next-generation sequencing. We found that returning incidental findings is likely cost effective for certain patient populations receiving next-generation sequencing, but that screening of generally healthy individuals is likely not cost effective based on current data and sequencing costs. We describe the development of our policy model, summarize key findings and discuss future research directions.

8:35 대형 소아병원의 게놈/정밀의학에 관한 사례 연구와 케이스 시리즈

StephenKingsmoreStephen F. Kingsmore, MB, ChB, BAO, D.Sc., FRCPath, Executive Director, Panomic Medicine, Children's Mercy - Kansas City

Over 5400 single-gene diseases are known, affecting 4-8% of children. Genome and exome sequencing are starting to change the approach to patient management in these diseases, specifically regarding early etiologic diagnosis and "N-of-1-genome" treatment strategies. Six large retrospective case studies have been or soon will be published providing the first measurements of costs and benefits of genomic/precision medicine in neurodevelopmental disorders and acutely ill infants. Two individual patient cases illustrate the transformative potential of genomic/precision medicine.

9:05 폐색성 관상동맥 질환 증상 환자의 평가:연령, 성별, 유전자 발현을 포함한 혈액 시험의 임상적 유효성, 임상 이용성, 경제적 이용성

MarkMonaneMark Monane, M.D., CMO, CardioDx

Patients with symptoms suggestive of obstructive coronary artery disease (CAD) frequently undergo unnecessary testing and procedures. Approximately $6.7 billion/year is spent on non-invasive and invasive testing in the U.S. in the non-diabetic population with no prior revascularization or myocardial infarction, yet some patients continue to be misdiagnosed. We present data on a blood test for use in the evaluation of obstructive CAD among symptomatic patients. Data of clinical validity (96% NPV), clinical utility (multiple change behavior studies) and economic utility (cost implications) will be presented.

9:35 스폰서 프레젠테이션

10:05 전시회장 휴식시간과 포스터 관람

10:45 임상 게노믹스의 신화와 현실

DavidMoskowitzDavid W. Moskowitz, M.D., Chairman, CEO, CMO & CSO, GenoMed, Inc.

Much of what passes for clinical genomics has been a waste of time and money, guided by unrealistic clinical paradigms. This has been fine, because the healthcare system is fundamentally anti-innovative, and is happy to waste the public's time and money. But for anybody who wants to capture marketshare, it is helpful to review what does and doesn't work.

11:15 패널 토론회:의료 비지니스 모델의 변환 시대에서 게놈 시퀀싱 서비스의 상환

At a time when payers are asking themselves, "Why pay for sequencing services?" come meet the people who are successfully crafting reimbursement arguments for the payers in disease areas as diverse as inherited genetic diseases and oncology. Find out the tactics that are working and why.

Moderator:
KatherineTynanKatherine Tynan, Ph.D., Tynan Consulting LLC





Panelists:


StephenKingsmoreStephen F. Kingsmore, MB, ChB, BAO, D.Sc., Children's Mercy - Kansas City






DavidMoskowitzDavid W. Moskowitz, M.D., GenoMed, Inc.






Additional Panelists to be Announced




12:00 pm 휴식시간

12:15 오찬 프레젠테이션 또는 개별 점심식사


의료를 위한 빅데이터 분석

1:30 의장 인사

John E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser Permanente


1:35 특별 프레젠테이션:데이터 분석에 의한 의료 영향 - Drug Discovery, 게노믹스 및 웨어러블 전망

SomaleeDattaSomalee Datta, Ph.D., Director, Bioinformatics, Stanford Center for Genomics & Personalized Medicine, Stanford University School of Medicine

In healthcare, we have an ever-increasing pile of data (aka, Data Tsunami, our favorite cliché). In the last two decades, we have also made tremendous strides in our computational bandwidth. We even found Higgs! What are the challenges with our healthcare data given the existing computational bandwidth?


2:05 중국의 잠재적 임상 게노믹스 응용

Bill Zheng, Ph.D., Director, Bioinformatics Section, Institute of Genetic Engineering, Southern Medical University

Next-generation sequencing and microarrays are being extended to clinical diagnosis. Disease can be diagnosed more efficiently and effectively, and the Chinese market has huge innovations in translational medicine. We present the marketing expansion in clinical medicine as well as in health management in China, plus developments in data mining and data management.

2:35 스폰서 프레젠테이션

3:05 전시회장 휴식시간과 포스터 관람

3:45 PatientsLikeMe:환자 보고 데이터를 위한 소셜 네트워크와 연구 플랫폼

MarciaNizzariMarcia M. Nizzari, MS, Vice President, Engineering, PatientsLikeMe, Inc.

With over 300,000 users, 2,300 conditions and 25 million+ medical datapoints collected, PatientsLikeMe provides a rich source of patient-reported phenotypic data. Patient-reported data provide key input into many areas of healthcare; clinical, payer, pharmaceutical and outcomes research will be positively disrupted by this new source of valuable information. This talk covers existing and proposed uses of those data to drive insights through integration with EHR, NGS data and other sources of -omics data.


4:15 특별 프레젠테이션:암 빅데이터 분석에서의 ONCOSCAPE 응용

EricHollandEric Holland, M.D., Ph.D., Director, Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center

We have developed a tool for visualization of combined clinical/molecular data for cancer patients. This tool has been used to interrogate multiple public and private datasets for molecular contributions to clinical behavior.


4:45 패널 토론회:분석학과 현실:건강과 질환의 유전자와 현상자 간 경계선의 불분명:온톨로지에 대한 영향과 착륙 지체

To maximize the clinical utility of genomic sequencing data, clinicians must ensure that both genomic and phenomic data is successfully integrated into the electronic health record (EHR) and other patient-centered platforms. This in turn requires understanding of technical infrastructure, security issues, policy requirements and the nature of the data itself. Learn about these topics and more from this panel of experts.

Panelists:

BeckySwainBecky Swain, Entrepreneur & Founding Member, Cloud Security Alliance






JohnMattisonJohn E. Mattison, M.D., Chief Medical Information Officer, Assistant Medical Director, Southern California Medical Group, Kaiser Permanente





Additional Panelists to be Announced



5:30 컨퍼런스 종료



첫째날 | 둘째날 | 셋째날

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English

» 스폰서

» 미디어 파트너


Catalog


국제컨퍼런스
Gii Event
이벤트 캘린더
의약품 관련 국제컨퍼런스

의약품 관련 국제컨퍼런스

메일링 서비스
메일링 서비스